🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — April 06, 2026

Across 49 filings dominated by proxy statements (over 20 DEF14A/DEFA14A/PREM14A for May 2026 AGMs), the S&P 500 Healthcare stream reveals accelerating M&A and clinical momentum amid routine governance, with Neurocrine Biosciences (NBIX) announcing a $2.9B acquisition of Soleno Therapeutics adding $190M 2025 revenue from VYKAT XR. Period-over-period trends show mixed results: Elvictor Group revenue +0.3% YoY but net loss swing to -$175k (EPS -$0.21 from +$0.24), NewtekOne loan originations +40% YoY to 961 units/$391M in Q1 2026, and Biogen flagging $34M Q1 IPR&D expenses (-$0.19 EPS). Biotech highlights include Praxis Precision Medicines' 77% placebo-adjusted seizure reduction in EMBRAVE trial and FDA priority review for relutrigine (PDUFA Sep 27, 2026). Portfolio-level patterns indicate positive capital deployment via acquisitions/deals (NBIX, ProCap, Six Flags divestiture) and stable guidance (NewtekOne Q1 EPS $0.37-0.47), but expense pressures in pharma; healthcare M&A premiums average ~42% (NBIX 34-51%). Actionable now: monitor May AGMs for comp/share approvals, NBIX close in 90 days.

24 high priority 25 medium 49 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 06, 2026

Across 50 DEF 14A proxy statements filed around April 6, 2026, a dominant theme is robust 2025 financial performance in 12 companies with disclosed metrics, averaging ~10% YoY revenue growth (e.g., JPM +record $185.6B, Howmet +11.1% sales, Quest +11.8%), strong ROE/ROTC (JPM 17%/20%, Horace Mann core ROE +300bps to 12.4%), and shareholder returns via buybacks/dividends (Assurant $468.3M returned, Middlesex 53 yrs dividend growth). Board refreshes and diversity are emphasized (Principal 50% women independents, MAA 7/9 independent), with 8 CEO/exec transitions noted as seamless (Core Molding, Alkermes). Mixed sentiments in REITs/apartments (MAA SS NOI -1.36% miss) contrast positive industrials/aerospace, but neutral governance dominates 70% filings. Capital allocation favors returns (Dorman $41M buybacks, Quest $450M repurchases) over aggressive M&A. Implications: Bullish for financials/insurers with payout growth, watch REITs for occupancy trends; portfolio-level margin stability (no widespread compression) supports overweight high-ROE names ahead of May 2026 meetings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 06, 2026

The IPO Pipeline stream reveals five new or contextual S-1 filings on April 6, 2026, dominated by mixed/neutral sentiments with Legence Corp. as the standout positive amid acquisition-driven growth. Period-over-period trends show stark contrasts: TEN Holdings' core virtual events revenue declined 15.6% YoY to $2.7M (88.2% of total), while physical events grew 33.3% to $0.4M, contrasting Legence's pro forma revenue expansion to $3.45B for 2025 via Bowers acquisition (up from historical $2.55B). High dilution risks proliferate in 20/20 Biolabs (80% conversion discounts on $712K crowdfunding + $70K notes, warrants for 3.5M shares), SPAC regulatory hurdles in Mountain Crest (PRC VIE/CSRC risks), and resale dynamics in LB Pharma. Capital allocation leans toward growth retention (no dividends across filings), with Legence financing $426.6M M&A via $200M debt post-$780M IPO proceeds. Portfolio-level theme: Early-stage biotechs/events face dilution/revenue headwinds, while services M&A signals consolidation; watch S-1 effectiveness for IPO catalysts.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — April 06, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include Indian regulatory disclosures on insolvencies (e.g., Reliance Home Finance CoC meetings, Aban Offshore NCLAT appeal), RBI money market operations showing persistent liquidity absorption (net -₹3.5L Cr to -₹4.5L Cr daily), and US SEC events like high-value M&A (Neurocrine-Soleno $2.9B takeover) and SPAC/IPO filings (Inflection Point $253M IPO, Aperture AC $90M target). Period-over-period trends reveal mixed financials: JPMorgan record $185.6B revenue/17% ROE (up significantly), Strategic Acquisitions net loss narrowed to $40k from $124k YoY with revenue to $0, MAA Core FFO beat ($8.77 vs $8.74 target) but TSR miss (-1.47% vs 4.07%), Madison Air op cash flow +118% YoY to $480M despite $4B debt. Critical developments flag takeovers (Neurocrine premium 34-51%), CEO retirements (TVA Jul 1), and dilutions (Greenpro shares doubled, Sammaan BlackRock stake -2.23%). Portfolio-level patterns show biotech M&A strength, Indian firm insolvency drags, and SPAC risks from PRC exposures; implications favor tactical plays in US biotech/healthcare amid neutral Indian liquidity.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 06, 2026

Across the 8 filings in the Financial Results & Earnings stream, small-cap and micro-cap companies predominantly reported mixed results with revenue growth in standout cases like SolarMax Technology (+296% YoY to $90.982M) and iQSTEL (+11.9% YoY to $316.9M), but widespread margin compression (e.g., SolarMax gross margin -550 bps to 4.6%, iQSTEL Q4 gross margin +72 bps but overall flat), net losses, and cash burn (e.g., STRATEGIC ACQUISITIONS -98% cash to $508, Nutra -90.1% to $3,603). Period-over-period trends show 4/8 companies with YoY revenue growth averaging +82% in winners, but 5/8 with widening or persistent net losses and deteriorating equity positions (e.g., Elvictor swung to -$175k loss, Neolara full asset impairment). Capital allocation leaned toward equity issuances and dividends (iQSTEL stock dividend $500k), with limited buybacks; no major M&A but forward-looking catalysts like Elvictor's nine Q1 2026 crew contracts signal potential turnarounds. Portfolio-level patterns indicate sector-agnostic cash constraints and operational volatility in finance/telecom/solar, implying high-beta opportunities amid Nasdaq compliance risks (SolarMax). Overall materiality skews high (avg 7.4/10), favoring selective longs on growth outliers while shorting cash burners.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 06, 2026

Across 40 filings in the USA Corporate Distress & Bankruptcy stream, outright distress is limited to one Chapter 11 bankruptcy (Charles & Colvard) and signals like DIP financing, forbearance agreements, covenant loosening, and reverse splits in 5 others, but the majority (28/40) involve new/expanded credit facilities, amendments, or notes issuances indicating proactive liquidity management amid potential pressures. No broad YoY/QoQ revenue declines reported, but isolated metrics show growth in acquired assets (e.g., VYKAT XR $190M 2025 revenue, INGREZZA $2.51B 2025) contrasting distress cases; sentiment skews positive/neutral (32/40) due to M&A premiums and financing access. Key themes include biotech M&A (NBIX-SLNO at 34-51% premiums, Profusa LOI), rail/RE securitizations, and covenant relief (e.g., Martin Midstream ICR to 1.65x, leverage to 5.5x). Portfolio-level pattern: 15/40 filings feature credit expansions/amendments (avg commitment +20-50%), signaling sector-wide deleveraging efforts; dilution risks in 4 cases (e.g., Greenpro shares doubled). Implications: Avoid deep distress names, favor M&A targets and strong refinancers; watch May-June catalysts for deal closes amid bankruptcy milestones.

40 high priority 40 total filings
· daily

US Executive Officer Management Changes SEC — April 06, 2026

Across 31 filings on USA executive and director changes from April 6, 2026, the dominant theme is robust C-suite and board refreshment, with 18 new appointments/promotions (9 CFOs, 4 CEOs, 5+ directors) signaling strategic hiring for growth amid AI, energy demand, and profitability inflection points, versus 13 departures/retirements/terminations. Positive sentiment prevails in 35% of cases (11/31), particularly tech/health/energy sectors with hires boasting cap markets, ops, and scaling expertise (e.g., Oracle 20%+ organic revenue growth, Nerdy FY2026 rev guidance $180-190M, EBITDA breakeven). Neutral sentiment in 55% reflects orderly transitions without disagreements, but mixed signals like FuelCell director opposition (3.6M votes against) and sudden terminations (HealthEquity CTO) flag potential governance risks. No broad YoY revenue declines noted, but portfolio-level trend shows margin improvements in 4 cases (Nerdy +1000bps EBITDA margin implied), continuity in large caps (Cheniere seamless Chairman shift), and heightened retention incentives (Heron exec severance enhancements). Market implications include near-term catalysts from retirements (TVA CEO July 1) and M&A closes (Hologic go-private April 7), favoring longs in growth refreshes while monitoring small-cap churn (e.g., Treasure Global, Solo Brands OTC suspension). Overall, bullish for sectors with proven succession (energy/tech) vs. watch utilities/small caps.

31 high priority 31 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 06, 2026

Across 31 SEC filings on USA Board Room Changes from April 6, 2026, there is elevated C-suite and board turnover with 18 appointments/promotions (e.g., 9 CFO roles) and 13 departures/retirements, skewed positive in tech, energy, and insurance sectors amid growth narratives. Key period trends include strong historical performance like Hologic's 65% revenue growth and 241% share price rise under retiring CEO, Oracle's >20% YoY organic revenue growth, and Nerdy's FY2026 guidance of $180-190M revenue with breakeven EBITDA (1,000bps margin expansion from 2025). Neutral sentiment dominates (19/31), but positive tones in 9 filings highlight expertise additions for scaling (e.g., AI-driven firms like DeFi Development Corp.). Critical implications: CFO influx signals financial discipline for expansion in energy (Expand Energy, Murphy USA) and tech (Oracle, Nerdy); CEO retirements at TVA (July 1) and Hologic (April 7 post-LBO) pose succession risks. Portfolio pattern: 7/12 energy/utility filings show leadership continuity for LNG/AI demand, contrasting sporadic director oppositions (e.g., FuelCell's 3.6M votes against). No broad margin compression but isolated incentives (Broadwind STIP payouts) amid capex reinvestment.

31 high priority 31 total filings
· daily

US Merger & Acquisition SEC Filings — April 06, 2026

The 11 filings reveal a surge in SPAC M&A pipeline activity, with two fresh IPOs (Inflection Point VI at $253M and QDRO at $200M, totaling $453M in new trusts) alongside extensions, updates, and delays in de-SPAC processes, signaling robust blank-check hunting amid favorable redemption dynamics. Completed takeovers dominate high-materiality events: Howmet's $1.8B aerospace acquisition, ProCap's AI-finance bolt-on adding $30B assets and thousands of users, Vireo's cannabis expansion to 10 states with 160+ dispensaries and 12M deliveries, and SWK's merger into RWAY involving $173.5M cash + 6.33M shares issued. Positive sentiment prevails in 4/11 filings (IPAC VI, Horizon, ProCap, Howmet, Vireo), contrasting neutral/mixed tones in SPAC delays and a low-materiality resignation. No explicit YoY/QoQ financial trends disclosed across filings, but capital deployed into trusts/deals highlights liquidity for M&A; SWK delisting and trust amendments indicate maturing SPAC lifecycle risks. Portfolio implication: Elevated US M&A momentum in SPACs, aerospace, fintech, and cannabis, with arbitrage ops in redemption premiums and de-SPAC catalysts through Q2 2026.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 06, 2026

Overnight SEC filings reveal a proxy-heavy stream dominated by DEF 14A/DEFA14A for upcoming May 2026 AGMs across financials (JPM, SCHW, GNW), REITs (MAA), and others, signaling routine governance but with positive comp tweaks (CNP exculpation). Biotech M&A surges with Neurocrine-Soleno $2.9B deal (51% premium, VYKAT XR $190M 2025 rev) and Profusa-Bio Insights $30M LOI, alongside strategic reviews (Playtika) and mergers (Clear Channel). Period trends mixed: Airsculpt rev -15.8% YoY to $151.8M (cases -15.6%), JPM record $185.6B rev/20% ROTCE, Laird Superfood acquiree +24% sales; aggregate 4/10 filings show rev declines avg -15%, offset by loss narrowing (Strategic Acquisitions net loss -67% YoY). Financing active with shelves (PodcastOne $150M, Ooma), SPAC IPOs (Inflection Point $253M), notes (Atlas $300M), but risks from going concerns (PodcastOne) and impairments (Airsculpt $4.6M). Capital allocation favors M&A/debt repayment over buybacks/dividends; insider activity limited but equity grants (Oxbridge NEOs). Key implications: Biotech/health catalysts near-term, monitor aesthetics weakness and SPAC dilutions.

21 high priority 23 medium 44 total filings
· daily

New Federal Contractors — April 04, 2026

This digest covers one civilian NASA contract totaling $181,839,613 in obligations, with zero defense-related awards. The Leland Stanford Junior University received the award from NASA's Goddard Space Flight Center for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a 25-year definitive cost-no-fee R&D effort in space science/applications (PSC AR22). The neutral signal (strength 4/10, materiality 6/10) highlights a stable long-term commitment but with only $25,928,889 outlayed to date against a base + all options value of $186,336,824. Highest-conviction signal is the low pricing risk and ~$7.3 million annual revenue estimate for Stanford's space R&D. Key watch item: outlay progress and performance toward the 2027-09-30 end date, amid full and open competition history.

1 total filings
· daily

Significant Contract Modifications ($10M+) — April 04, 2026

NASA's $181,839,613 contract modification to The Leland Stanford Junior University represents 100% civilian agency spending (0/1 defense-related), focusing on the Goddard Space Flight Center's Solar Dynamics Observatory Heliospheric and Magnetic Imager (HMI) project. This definitive cost-no-fee award, active since 2002-10-15 through 2027-09-30, highlights long-term commitment to space science R&D under full and open competition. The neutral signal (avg strength 4/10) balances sustained funding against low outlays of $25,928,889 to date and modest annual revenue estimate of ~$7.3M. Highest-conviction signal is the durability of NASA's space applications R&D investments (PSC AR22, NAICS 541710). Key watch item: outlay progress beyond $25,928,889 and execution toward 2027-09-30 amid potential civilian budget shifts.

1 total filings
· daily

Contract Deobligations Alert — April 04, 2026

This Contract Deobligations Alert digest synthesizes one civilian NASA contract totaling $181,839,613 in obligations to The Leland Stanford Junior University, with a 0/1 defense-related split indicating pure civilian exposure. The dominant agency and sector theme is NASA's long-term commitment to space science/applications R&D via the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation. The highest-conviction signal is neutral (4/10 strength), reflecting low outlays of $25,928,889 against the $181,839,613 obligation on a 25-year definitive cost-no-fee contract awarded in 2002. A key risk is stalled outlay progress amid the deobligation alert context, with annual revenue estimated at ~$7.3 million but uncertain due to uneven spending. Investors in civilian space R&D should watch performance toward the 2027-09-30 end date for potential funding continuity or cuts.

1 total filings
· daily

Contract Option Exercises — April 04, 2026

NASA's Goddard Space Flight Center exercised options totaling $181,839,613 on a single long-term contract with The Leland Stanford Junior University, representing 100% civilian exposure with zero defense-related activity. This neutral signal (strength 4/10, materiality 6/10) reflects sustained commitment to space science R&D via the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a definitive cost-no-fee award under full and open competition running through September 30, 2027. Only $25,928,889 has been outlayed to date out of a base + all options value of $186,336,824, implying an estimated annual revenue of ~$7.3 million amid uneven spending. The highest-conviction signal is the low pricing risk from the cost-no-fee structure, providing durability outside CR/NDAA volatility. Key watch item: outlay progress beyond $25.9 million and performance toward the 2027 end date.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 04, 2026

A single mega contract totaling $181,839,613 in obligations was analyzed for the period April 04, 2026 to April 04, 2026, representing 100% civilian exposure (0/1 defense-related) dominated by NASA's Goddard Space Flight Center. The Leland Stanford Junior University received this definitive cost-no-fee award in 2002 for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, spanning 25 years to 2027-09-30 with only $25,928,889 outlayed to date out of a $186,336,824 base + options value. The highest-conviction signal is neutral (4/10 strength, 6/10 materiality), reflecting long-term space R&D stability tempered by slow outlay progress under full and open competition. Dominant sector theme is civilian space science/applications R&D (PSC AR22, NAICS 541710). Key risk/watch item: monitor outlay progression beyond $25,928,889 and performance toward the 2027-09-30 end date amid cost-no-fee structure.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 04, 2026

This digest covers a single high-value federal grant totaling $181,839,613 in obligations, entirely civilian (NASA) with zero defense-related contracts. The dominant agency is NASA via Goddard Space Flight Center, funding The Leland Stanford Junior University's Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation. The highest-conviction signal is neutral (4/10 strength), reflecting a long-term (25-year) cost-no-fee R&D commitment in space science/applications under full and open competition. Only $25,928,889 has been outlayed to date against a base + all options value of $186,336,824, implying an annual revenue estimate of ~$7.3 million. Key risk/watch item: outlay progress beyond current levels and performance toward the 2027-09-30 end date amid low pricing risk.

1 total filings
· daily

General Federal Contracts — April 04, 2026

NASA's Goddard Space Flight Center has obligated $181,839,613 to The Leland Stanford Junior University for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, representing 100% of the period's aggregate value with zero defense-related contracts. This single civilian award underscores a long-term commitment to space science R&D under a definitive cost-no-fee structure awarded in 2002 and extending to 2027-09-30. The highest-conviction signal is neutral (4/10 strength), reflecting steady multi-decade funding despite only $25,928,889 outlayed to date against a base + options value of $186,336,824. Full and open competition signals no immediate moat concerns, with low pricing risk. A key watch item is outlay progress and performance milestones toward the 2027 end date amid potential uneven R&D spending.

1 total filings
· daily

All NASA Contracts — April 04, 2026

NASA's single contract obligation of $181,839,613 during April 04, 2026, to April 04, 2026, is fully civilian with zero defense-related awards, centered on Goddard Space Flight Center's long-term space science R&D funding. The Leland Stanford Junior University received the entirety for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a 25-year cost-no-fee contract (2002-2027) under full and open competition. The highest-conviction signal is neutral (4/10 strength), reflecting stable but low outlays of $25,928,889 against a base + options value of $186,336,824. Dominant theme is sustained NASA commitment to heliophysics R&D via academic partners. Key risk/watch item: monitor outlay progression beyond $25.9M and performance toward the 2027-09-30 end date amid uneven spending.

1 total filings
· daily

Biotech Small-Cap Approvals — April 03, 2026

The FDA approved 7 'Other' products from March 27-31, 2026 (captured in the April 03 period), featuring 0 NMEs, 0 biosimilars, and 0 label expansions, with all signals rated neutral due to generic/ANDA or standard original approvals lacking premium designations. No dominant therapeutic area theme is evident, as indications remain unspecified across the board. Highest-conviction signal is TEVA PHARMACEUTICALS, INC.'s original BLA 761385 approval (materiality 4/10), a modest portfolio addition for the sponsor with low pricing power and no exclusivity. Key risk/watch item is negligible commercial differentiation in crowded generic markets, with post-approval launches as the sole near-term catalysts.

7 total filings
· daily

NME Blockbuster Approvals — April 03, 2026

The FDA approval period of April 3 to April 3, 2026, featured 1 other approval (0 NMEs, 0 biosimilars, 0 label expansions), centered on ELI LILLY AND CO's Unknown under Priority Review. No dominant therapeutic area theme is evident due to undisclosed details. The highest-conviction signal is ELI LILLY AND CO's Unknown NME approval, a bullish event (strength 8/10, materiality 8/10) signaling pipeline execution and potential commercial upside in the NME Blockbuster Approvals stream. Priority Review designation highlights FDA recognition of significant benefit. Key risk/watch item: Limited visibility into peak sales, exclusivity, pricing, and market position (all NOT_DISCLOSED), warranting post-approval commercialization monitoring.

1 total filings